X4 Pharmaceuticals appoints John K. Celebi as COO
Mr. Celebi brings to X4 over 20 years of experience building innovative entrepreneurial biotechnology companies.
Mr. Celebi most recently served as Chief Business Officer of Igenica Biotherapeutics, a biotechnology company focused on immunotherapies and other cancer medicines, where he was responsible for the company’s corporate and business development functions, as well as operations.
Prior to Igenica, Mr. Celebi held leadership roles of increasing responsibility at ArQule, a publicly traded biotechnology company focused on the advancement of differentiated small molecule kinase inhibitors for cancer patients, including Vice President, Business Development, New Product Planning and Alliance Management.
From 2001 to 2003, he was Director of Business Development at Cyclis Pharmaceuticals, which was acquired by ArQule.
Mr. Celebi has extensive transactional expertise for public and private biotechnology companies, including strategic alliances, R&D collaborations, joint ventures, strategic M&A and equity financings.
He holds a BS in Biophysics from the University of California, San Diego, and an MBA from Carnegie Mellon University. ■
LATEST MOVES FROM Massachusetts
- Dunkin' Brands Group CFO Paul Carbone to leave
- Abpro appoints Gavin MacBeath as CSO
- bluebird bio appoints two executives
- Biogen appoints Anirvan Ghosh as SVP
- Brightcove adds Diane Hessan to board
More inside POST
Uncertainty can make people work harder Leadership